Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.2K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

3.5K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.5K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

536
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
536
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Association of bronchoalveolar lavage cellular analysis and radiological findings in fibrotic interstitial lung diseases.

BMJ open respiratory research·2026
Same author

Correction: Progressive pulmonary fibrosis.

European radiology·2026
Same author

Case Report: Decoding genetic risks of vascular parkinsonism: a case series.

Frontiers in genetics·2025
Same author

APOE genetic variability in an Egyptian cohort of PD.

Frontiers in neuroscience·2025
Same author

Evaluation of the safety of short-term follow-up CT for the management of consolidation in lung cancer screening.

European radiology·2025
Same author

Deep-learning CT imaging algorithm to detect usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease: association with disease progression and survival.

Rheumatology (Oxford, England)·2024

Video Experimental Relacionado

Updated: Jan 8, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

860

Fibrosis pulmonar progresiva

Ramey Bajwa1, Drew Lancaster2, Sujal R Desai3,4

  • 1Department of Interstitial Lung Disease, Royal Brompton Hospital, London, UK. rameybajwa@gmail.com.

European radiology
|December 19, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La fibrosis pulmonar progresiva (FPP) imita la fibrosis pulmonar idiopática (FPI) y aumenta la mortalidad. La identificación de la progresión radiológica en TC es crucial para el tratamiento antifibrótico oportuno y para frenar el deterioro de la función pulmonar.

Palabras clave:
AntifibróticosTomografía computarizadaNintedanibFibrosis pulmonar progresivaProgresión radiológica de la fibrosis

Más Videos Relacionados

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

807
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.5K

Videos de Experimentos Relacionados

Last Updated: Jan 8, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

860
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

807
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.5K

Área de la Ciencia:

  • Neumología
  • Radiología
  • Imagenología médica

Sus antecedentes:

  • Un subconjunto de casos de fibrosis pulmonar no idiopática (FPI) exhibe una trayectoria de fibrosis pulmonar progresiva (FPP).
  • La FPP se asocia con una mayor mortalidad de los pacientes y mimetiza clínicamente la FPI.
  • La identificación de la FPP es fundamental para el manejo del paciente y el pronóstico.

Objetivo del estudio:

  • Definir los criterios de progresión radiológica para la identificación de la FPP.
  • Destacar el papel de los radiólogos en el manejo de pacientes con FPP.
  • Subrayar la importancia de la detección temprana para la terapia antifibrótica.

Principales métodos:

  • Análisis de TC seriadas de alta resolución.
  • Evaluación de los cambios en la extensión y gravedad de la fibrosis a lo largo del tiempo.
  • Evaluación radiológica de la progresión en casos de no FPI.

Principales resultados:

  • La progresión radiológica en la FPP se caracteriza por un aumento de la extensión general de la fibrosis.
  • La progresión también puede manifestarse como un aumento de la gravedad de la fibrosis con una extensión general sin cambios.
  • La identificación radiológica precisa permite una intervención oportuna.

Conclusiones:

  • Los radiólogos son fundamentales en el diagnóstico de la FPP a través de la evaluación por TC.
  • La identificación de la progresión radiológica permite la iniciación de fármacos antifibróticos.
  • El tratamiento antifibrótico temprano puede mitigar significativamente el deterioro de la función pulmonar en la FPP.